Form 8-K - Current report:
SEC Accession No. 0001140361-25-023553
Filing Date
2025-06-25
Accepted
2025-06-25 07:32:04
Documents
12
Period of Report
2025-06-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ef20051006_8k.htm   iXBRL 8-K 27270
  Complete submission text file 0001140361-25-023553.txt   155342

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA roiv-20250624.xsd EX-101.SCH 3979
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE roiv-20250624_lab.xml EX-101.LAB 21966
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE roiv-20250624_pre.xml EX-101.PRE 16042
14 EXTRACTED XBRL INSTANCE DOCUMENT ef20051006_8k_htm.xml XML 4208
Mailing Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB
Business Address 7TH FLOOR, 50 BROADWAY LONDON UNITED KINGDOM United Kingdom SW1H 0DB 441-295-5950
Roivant Sciences Ltd. (Filer) CIK: 0001635088 (see all company filings)

EIN.: 981173944 | State of Incorp.: D0 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-40782 | Film No.: 251070972
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)